Perjeta (pertuzumab)

pCPA File Number: 21742

Negotiation Status:

Concluded without agreement

Indication(s):

Breast cancer, Locally advanced, inflammatory, or early stage HER2-positive (either 2 cm in diameter or node positive), for neoadjuvant treatment of patients (in combination with trastuzumab and chemotherapy)

Sponsor/Manufacturer:

Hoffmann-La Roche Ltd.

CDA-AMC Project Number:

PC0241-000

pCPA Engagement Letter Issued:

2023-06-28

Negotiation Process Concluded:

2023-12-21